Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

Abstract Background Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non‐small‐cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second‐line treatment after chemoimmunotherap...

Full description

Bibliographic Details
Main Authors: Masaki Ishida, Kenji Morimoto, Tadaaki Yamada, Shinsuke Shiotsu, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takayuki Takeda, Koichi Takayama
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Thoracic Cancer
Subjects:
chemoimmunotherapy
docetaxel plus ramucirumab
non‐small‐cell lung cancer
performance status
Online Access:https://doi.org/10.1111/1759-7714.14236

Internet

https://doi.org/10.1111/1759-7714.14236

Similar Items